Silber-Sponsor Boehringer Ingelheim
Value through innovation
Boehringer Ingelheim develops therapeutic breakthroughs that transform lives – today and for generations to come. It is divided into two business areas: Human Pharma and Animal Health. The Human Pharma business is the mainstay of the company’s activities, underpinned by an innovative portfolio. In animal health, Boehringer Ingelheim is one of the world’s leading providers of vaccines and therapeutics.
Family-owned since its foundation in 1885, Boehringer Ingelheim is one of the world’s leading research-based pharmaceutical companies, serving over 130 markets. Approximately 54,500 of its employees strive to make a real and significant contribution to the health of humans and animals alike. In 2024, Boehringer Ingelheim achieved net sales of EUR 26,796 million.
Focus on research and development
The company’s goal is to research and develop fi rst-in-class breakthrough medicines that change the lives of people for whom there are no satisfactory treatments available. With our innovations we have already transformed the health of both human and animal patients around the world. Boehringer Ingelheim’s human pharma research focuses on therapeutic areas of cardiovascular and metabolic health, cancer, mental health, eye health and infl ammatory diseases. In animal health, the research focus areas include infectious diseases, noninfectious diseases, and parasiticides.
The company’s central R&D facilities are located in Germany, the USA, Austria, Japan, and France as well as China.
Boehringer Ingelheim has consistently increased its R&D expenses in recent years. A total of approximately EUR 6.2 billion, corresponding to 23.2% of consolidated sales, was invested in the R&D of new medicinal products, again an increase compared to the previous year.
Additional information can be found on: